CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

RSV vaccines could get broader CDC backing for adults aged 50-59 at risk after an endorsement from an agency's expert panel. Read more here.

WASHINGTON — (AP) — Shortly before he was forced to resign, the nation's top vaccine regulator says he refused to grant Health Secretary Robert F. Kennedy Jr.'s team unrestricted access to a ...

Read full article: Save big on everyday computing—get a 2-in-1 touchscreen Chromebook for ... who were discharged for refusing the COVID-19 vaccine, as it works to implement President Donald ...

ABL Bio Inc., a South Korean biotech company, will license out its proprietary blood-brain barrier shuttle platform, called the Grabody-B, to UK-based pharmaceutical giant GSK plc in a deal expected ...

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South Korean company’s tech to bypass the blood-brain barrier. ABL Bio has ...

(The Hill) – Health and Human Services Secretary Robert F. Kennedy Jr. touted the measles, mumps and rubella (MMR) vaccine as the “most effective” way to prevent the spread of measles during ...

ABL Bio Inc. announced April 7 that it sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier (BBB) penetrating ...